Canada markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
12.89-0.16 (-1.23%)
At close: 04:00PM EST
12.89 0.00 (0.00%)
After hours: 07:55PM EST

Teva Pharmaceutical Industries Limited

124 Dvora HaNevi’a Street
Tel Aviv 6944020
Israel
972 3 914 8213
https://www.tevapharm.com

Sector(s)Healthcare
IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees35,001

Key Executives

NameTitlePayExercisedYear Born
Mr. Eliyahu Sharon KalifExecutive VP & CFO2.01MN/A1973
Mr. Eric DrapeExecutive Vice President of Global Operations1.91MN/A1962
Mr. Mark SabagExecutive Vice President of International Markets Commercial1.92MN/A1971
Mr. Richard D. FrancisPresident, CEO & DirectorN/AN/A1968
Mr. Amir WeissSenior VP & Chief Accounting OfficerN/AN/A1977
Ran MeirHead of Investor RelationsN/AN/AN/A
Dov BergwerkActing Chief Legal Officer & Corporate SecretaryN/AN/AN/A
Kathleen VeitSenior Vice President, Global Compliance & Ethics OfficerN/AN/AN/A
Ms. Vikki ConwayActing Head of Global Human ResourcesN/AN/AN/A
Mr. Kevin C. MannixSenior Vice President of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Corporate Governance

Teva Pharmaceutical Industries Limited’s ISS Governance QualityScore as of February 1, 2024 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder Rights: 5; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.